ReviewImmunological reviews2019
Cellular therapy: Immune-related complications.
Review in Immunological reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 70 citations in OpenAlex.
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- T cell engagers: expanding horizons in oncology and beyond.British journal of cancer · 2025Review
- Constructing a prognostic model for osteosarcoma based on centrosome-related genes and identifying potential therapeutic targets of paclitaxel.Scientific reports · 2025Article
- Enhanced anti-tumor efficacy of "IL-15 and CCL19" -secreting CAR-T cells in human glioblastoma orthotopic xenograft model.Frontiers in oncology · 2025Article
- γδ T cells in hematological malignancies: mechanisms and therapeutic strategies.Blood science (Baltimore, Md.) · 2025Review
- Double-camouflaged tellurium nanoparticles for enhanced photothermal immunotherapy of tumor.Journal of nanobiotechnology · 2024Article
- Longitudinal plasma proteomics in CAR T-cell therapy patients implicates neutrophils and NETosis in the genesis of CRS.Blood advances · 2024Article
- Drug-induced AF: Arrhythmogenic Mechanisms and Management Strategies.Arrhythmia & electrophysiology review · 2024Review
- Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.Archivum immunologiae et therapiae experimentalis · 2023Review
- Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.Cells · 2023Review
- Challenges of Anti-Mesothelin CAR-T-Cell Therapy.Cancers · 2023Review
- Review
- Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.Blood · 2022Article
- Engineering CpG-ASO-Pt-Loaded Macrophages (CAP@M) for Synergistic Chemo-/Gene-/Immuno-Therapy.Advanced healthcare materials · 2022Article
- Infection complications in febrile chimeric antigen receptor (CAR)-T recipients during the peri-CAR-T cell treatment period examined using metagenomic next-generation sequencing (mNGS).Cancer communications (London, England) · 2022Article
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Cytotoxic Efficiency of Human CD8Frontiers in immunology · 2022Article
- Article
- Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The advent of chimeric antigen receptor T (CAR-T) and the burgeoning field of cellular therapy has revolutionized the treatment of relapsed/refractory leukemia and lymphoma. This personalized "living therapy" is highly effective against a number of malignancies, but this efficacy is tempered by side effects relatively unique to immunotherapies, including CAR-T. The overwhelming release of cytokines and chemokines by activated CAR-T and other secondarily activated immune effector cells can lead to cytokine release syndrome (CRS), which can have clinical and pathophysiology similarities to systemic inflammatory response syndrome and macrophage activating syndrome/hemophagocytic lymphohistiocytosis. Tocilizumab, an anti-IL6 receptor antibody, was recently FDA approved for treatment of CRS after CAR-T based on its ability to mitigate CRS in many patients. Unfortunately, some patients are refractory and additional therapies are needed. Patients treated with CAR-T can also develop neurotoxicity and, as the biology is poorly understood, current therapeutic interventions are limited to supportive care. Nevertheless, a number of recent studies have shed new light on the pathophysiology of CAR-T-related neurotoxicity, which will hopefully lead to effective treatments. In this review we discuss some of the mechanistic contributions intrinsic to the CAR-T construct, the tumor being treated, and the individual patient that impact the development and severity of CRS and neurotoxicity. As CAR-T and cellular therapy have redefined the concept of personalized medicine, so too will personalization be necessary in managing the unique side effects of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.